MRNA ModernacompanySEC Filings & Insider Trading Activity 2026
Latest Moderna (MRNA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 20, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on May 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Moderna (MRNA) (SEC CIK 1682852), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Development and commercialization of mRNA-based vaccines and therapeutics across infectious diseases, oncology, and rare diseases
- • New product: Launch of mNEXSPIKE COVID vaccine in Q3 2025, now leading US retail product; ongoing filings for flu+COVID and flu-only vaccines in multiple regions
Risk Factors
- • Regulatory risk: FDA refusal-to-file letter on seasonal flu vaccine mRNA-1010; amended BLA accepted with PDUFA date August 5, 2026
- • Geopolitical risk: COVID and RSV vaccine manufacturing now onshored in US, Australia, UK, and Canada under government agreements for local supply and pandemic preparedness
Management Discussion & Analysis
- • Revenue $1.944B, down 40% YoY ($3.236B in 2024); net product sales $1.818B, down 42% YoY ($3.109B in 2024) due to lower COVID vaccine demand
- • Operating loss $3.074B vs $3.945B; cost of sales $868M (48% of net product sales) vs $1.464B (47%); R&D $3.132B down 31%, SG&A $1.018B down 13%
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Section 'mda' was empty or not found.
Risk Factors
- • No material changes to risk factors from 2024 Form 10-K
- • Continued dependency on successful development and commercialization of vaccine candidates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Moderna settles all global LNP patent litigation with Arbutus/Genevant for a mandatory $950M lump sum due by July 8, 2026
- • Additional $1.3B contingent payment triggered if Federal Circuit rejects Moderna's §1498 defense; worst-case total exposure = $2.25B
Annual Reports Archive10-K
AI-powered analysis of Moderna (MRNA) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Moderna (MRNA) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Moderna (MRNA) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $19.3B | $6.8B | $3.2B | $1.9B |
| Operating Income | $9.4B | -$4.2B | -$3.9B | -$3.1B |
| Net Income | $8.4B | -$4.7B | -$3.6B | -$2.8B |
| Op. Margin | 48.9% | -61.9% | -121.9% | -158.1% |
| Net Margin | 43.4% | -68.8% | -110.0% | -145.2% |
| Balance Sheet | ||||
| Total Assets | $25.9B | $18.4B | $14.1B | $12.3B |
| Equity | $19.1B | $13.9B | $10.9B | $8.7B |
| ROE | 43.7% | -34.0% | -32.7% | -32.6% |
Source: XBRL financial data from Moderna (MRNA) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | May 1, 2026 | — | — | — |
8-K | Mar 5, 2026 | — | Analysis | — |
10-K | Feb 20, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 13, 2026 | — | — | |
8-K | Feb 11, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Jan 5, 2026 | — | — | |
8-K | Nov 24, 2025 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 1, 2025 | Jun 30, 2025 | Analysis | |
10-Q | May 1, 2025 | Mar 31, 2025 | Analysis | |
10-K | Feb 21, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Feb 23, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 24, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 25, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — |
Frequently Asked Questions
What are the latest MRNA SEC filings in 2026?
Moderna (MRNA) has filed a 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did MRNA file its most recent 10-K annual report?
Moderna (MRNA) filed its most recent 10-K annual report on February 20, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view MRNA 10-Q quarterly reports?
Moderna (MRNA)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every MRNA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has MRNA filed recently?
Moderna (MRNA)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find MRNA insider trading activity (Form 4)?
SignalX aggregates every MRNA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does MRNA file with the SEC?
Moderna (MRNA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MRNA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Moderna (MRNA).
What is MRNA's SEC CIK number?
Moderna (MRNA)'s SEC CIK (Central Index Key) number is 1682852. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1682852 to look up all MRNA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find MRNA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Moderna (MRNA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Moderna SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 28+ filings.